Biobijou Co Ltd

Biobijou maintains a strong liquidity position with a current ratio of 30.2, significantly above the industry median, and a cash and equivalents balance of KRW 11.64 billion, which represents 18.2% of total assets. The company's low debt-to-equity ratio of 0.01 indicates a conservative capital structure, with long-term debt accounting for just 0.6% of total liabilities. The liquidity FPT score of 0.94 confirms minimal near-term liquidity risk, supported by positive free cash flow of KRW 4.14 billion. Profitability metrics show a return on equity (ROE) of 6.7% and return on assets (ROA) of 6.5%, both above the industry median for pharmaceutical firms. Gross margin stands at 55.9%, with operating margin at 14.8%, indicating efficient cost control and pricing power. Net income of KRW 4.15 billion reflects a 14.9% margin on revenue of KRW 28.49 billion. The company operates as a single-segment entity, with all revenue generated domestically in South Korea. This geographic concentration exposes Biobijou to local regulatory and economic conditions but avoids currency and cross-border operational risks. Revenue growth has been stable, with a 12-month outlook projecting a 4.2% increase in revenue. Free cash flow is expected to remain positive, driven by controlled capital expenditures and strong gross margins. The company's operating cash flow was negative in the latest period, but this is attributed to working capital adjustments rather than operational performance. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares in the past 12 months, and diluted shares remain unchanged at 15.04 million. No ATM or shelf registration disclosures were identified in the latest filings. Recent filings and transcripts show no material changes in business strategy or regulatory exposure. The company continues to focus on expanding its product portfolio in the domestic market, with no announced international expansion plans. No material litigation or compliance issues were disclosed in the latest 10-K equivalent filing.